GKIM
CRL icon

GW&K Investment Management’s Charles River Laboratories CRL Stock Holding History

GW&K Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5M Sell
90,608
-4,549
-5% -$810K 0.16% 214
2026
Q1 		$16.4M Sell
95,157
-5,868
-6% -$1.09M 0.14% 222
2025
Q4 		$20.2M Buy
101,025
+4,371
+5% +$793K 0.17% 205
2025
Q3 		$15.1M Buy
96,654
+8,341
+9% +$1.32M 0.13% 231
2025
Q2 		$13.4M Sell
88,313
-97
-0.1% -$12.9K 0.12% 238
2025
Q1 		$13.3M Buy
88,410
+25,744
+41% +$4.32M 0.12% 238
2024
Q4 		$11.6M Buy
62,666
+2,953
+5% +$569K 0.1% 254
2024
Q3 		$11.8M Buy
59,713
+1,051
+2% +$218K 0.1% 245
2024
Q2 		$12.1M Buy
58,662
+4,001
+7% +$907K 0.11% 241
2024
Q1 		$14.8M Sell
54,661
-849
-2% -$203K 0.13% 213
2023
Q4 		$13.1M Buy
55,510
+9,782
+21% +$1.92M 0.12% 224
2023
Q3 		$8.96M Buy
45,728
+16,790
+58% +$3.45M 0.09% 244
2023
Q2 		$6.08M Buy
28,938
+1,000
+4% +$199K 0.06% 260
2023
Q1 		$5.64M Buy
27,938
+3,744
+15% +$848K 0.05% 260
2022
Q4 		$5.27M Buy
24,194
+13,852
+134% +$3.02M 0.05% 258
2022
Q3 		$2.04M Sell
10,342
-489
-5% -$106K 0.02% 302
2022
Q2 		$2.32M Sell
10,831
-495
-4% -$121K 0.03% 296
2022
Q1 		$3.22M Sell
11,326
-266
-2% -$82K 0.03% 290
2021
Q4 		$4.37M Sell
11,592
-3,710
-24% -$1.44M 0.04% 274
2021
Q3 		$6.32M Sell
15,302
-75
-0.5% -$31.1K 0.06% 244
2021
Q2 		$5.69M Sell
15,377
-8,925
-37% -$2.98M 0.05% 264
2021
Q1 		$7.04M Sell
24,302
-3,715
-13% -$1.03M 0.06% 240
2020
Q4 		$7M Sell
28,017
-10,620
-27% -$2.53M 0.07% 239
2020
Q3 		$8.75M Sell
38,637
-2,050
-5% -$425K 0.11% 217
2020
Q2 		$7.09M Buy
40,687
+2,800
+7% +$447K 0.1% 219
2020
Q1 		$4.78M Sell
37,887
-8,025
-17% -$1.2M 0.08% 219
2019
Q4 		$7.01M Sell
45,912
-3,030
-6% -$420K 0.09% 223
2019
Q3 		$6.48M Sell
48,942
-2,585
-5% -$347K 0.09% 218
2019
Q2 		$7.31M Buy
+51,527
New +$6.99M 0.11% 217

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

GW&K Investment Management's CRL Position: Q2 2026 in Review

GW&K Investment Management reduced its Charles River Laboratories (CRL) stake by 4.8% in Q2 2026, selling an estimated $810K and leaving 90,608 shares worth $20.5M. The position accounts for 0.16% of the portfolio, ranked #214.

GW&K Investment Management first reported a position in CRL in Q2 2019 and has held it in 29 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • GW&K Investment Management held 90,608 shares of Charles River Laboratories worth $20.5M as of Q2 2026.
  • GW&K Investment Management sold 4,549 Charles River Laboratories shares in Q2 2026, an estimated $810K.
  • Charles River Laboratories made up 0.16% of GW&K Investment Management's portfolio in Q2 2026, its #214 holding.
  • GW&K Investment Management first reported a position in Charles River Laboratories in Q2 2019 and has held it in 29 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.